Moreover, andrographolide and its derivatives, namely, 14-deoxy-11,12-didehydroandrographolide (14-DDA) and 3,19-isopropylidene andrographolide (IPAD), were active against human papillomavirus-16 (HPV16) infection, which is a high-risk human papillomavirus (HR-HPV) subtype causing cervical cancer; this is due to their abilities to inhibit E6 oncoprotein expression and restore p53 expression [121,122]. This evidence concerns the gene TP53 and cervical carcinoma.